The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal Trade Commission's office of competition under President George W. Bush. Schmidt, who will be discussing the antitrust landscape at The Deal Economy 2010 conference Nov. 18 and 19, says based on reports about the review, it seems regulators expanded their investigation beyond what would have taken place under the previous administration. See the video below or
download it at iTunes. - Suzanne Stevens
Even in a period when things like toxic credit default swaps and noxious structured investment vehicles dominate the conversation in many parts of the deal community, people are still willing to take the time to recognize skill and achievement in the strategic transactions that help those companies adapt and grow.
Juergen Lasowski
And the winners are...
